Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020General feeling that failures are bound to happen - but that their approaches can succeed
Join the club for FREE to access the whole archive and other member benefits.
CEO at Juvenescence and chairman of Portage Biotech
Dr. Gregory Bailey is chairman of Portage Biotech, Inc. a publicly traded drug development company and was previously managing partner of Palantir Group, Inc., a merchant bank specialising in biotech and intellectual property. He has over 15 years of experience in investment banking and has founded several companies.
Along with comprehensive experience in healthcare, finance and
medicine, Greg brings an extensive involvement in corporate governance.
He has co-founded and served on multiple public and private company
boards of directors, such as Palantir Group, Inc., Ascent Healthcare
Solutions, VirnetX Inc. (VHC:AMEX), Portage Biotech Inc. (PTGEF: OTCBB),
DuraMedic Inc., and MediqVentures Ltd.
Visit website: https://juvenescence.ltd/team/
See also: Juvenescence - Developing therapies against different aging related diseases.
Details last updated 21-Nov-2019
04-Feb-2025
Longevity summit organised by Hevolution Foundation (Riyadh,Saudi Arabia)
10-May-2022
Juvenescence webinar about the latest research and developments on future of longevity investment
27-Sep-2023 to 29-Sep-2023
Conference gathering longevity experts and investors at one place hosted by Marc P. Bernegger, Dr. Tobias Reichmuth and Daniel Koetser
04-May-2021 to 07-May-2021
The virtual event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX).
26-Feb-2022 to 27-Feb-2022
Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)
General feeling that failures are bound to happen - but that their approaches can succeed
Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration
Good summary of some major investments in life extension companies
Antoxerene partners with Juvenescence to discover drugs that clear senescent cells
LyGenesis seeks to use a patient’s own lymph nodes as bioreactors to grow functioning ectopic organs
We are at an inflection point for the treatment of aging. We can generate molecules with specifi...